ArticleBMC public health2025
Evaluation of factors related to longitudinal CD4 count and the risk of death among HIV-infected patients using Bayesian joint models.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn many epidemiological HIV studies, patients are frequently monitored over time to predict their survival by examining their CD4 levels repeatedly. This study aims to evaluate factors related to longitudinal CD4 count and the risk of death among HIV-infected patients using Bayesian joint models.
methodsThe information of patients who were infected with HIV in Fars Province, from 2011 to 2016 and followed up until 2022 was used in this study. A joint model of count longitudinal outcome and time to death is used to model information of HIV patients.
resultsThe majority of patients were male (67.8%) with a median age of 34 years. During the follow-up, 212 patients (28.0%) died. The age-standardized mortality and incidence rates from 2011 to 2016 were 0.496 and 2.49 per 100,000 person-years respectively. The 1-year and 5-year survival rates are 91% (95%CI: 89%, 93%) and 79% (95%CI: 77%, 82%) respectively. There is a significant association in this model between the CD4 cell count and the risk of death. Age, addiction, and men were all significantly linked to CD4 cell count. Age was positively correlated with the risk of death. Men, those with hepatitis B and history of addiction had a higher risk of death.
conclusionThis study uses the power of Bayesian joint models to explore the complex relationship between changes in CD4 counts over time and the risk of death in patients with HIV. Our findings highlight a strong and statistically significant connection between CD4 cell count and mortality risk. By modeling CD4 counts alongside survival data, we offer a deeper understanding of the factors influencing patient outcomes over time, significantly enhancing traditional separate modeling methods. This comprehensive approach leads to more accurate predictions, ultimately aiding in better-informed clinical decisions for HIV care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.